Literature DB >> 27197871

Comparison of botulinum toxin-A injection in lacrimal gland and conjunctivodacryocystorhinostomy for treatment of epiphora due to proximal lacrimal system obstruction.

P Kaynak1, G O Karabulut1, C Ozturker1, K Fazil1, Y O Arat2, I Perente3, S Akar4, O F Yilmaz3, A Demirok3,5.   

Abstract

PurposeTo investigate and compare the efficacy of botulinum toxin-A injection in the lacrimal gland and conjunctivodacryocystorhinostomy surgery for the treatment of epiphora caused by proximal lacrimal system obstruction.MethodsCharts of the patients with proximal canalicular obstruction who had undergone conjunctivodacryocystorhinostomy with permanent tube insertion (18 patients, group 1) or 4 units of botulinum toxin-A injection in the palpebral lobe of the lacrimal gland (20 patients, group 2) were reviewed retrospectively. The upper lacrimal system obstruction was diagnosed by lacrimal system irrigation. Schirmer-1 test and Munk epiphora grading for evaluation of epiphora were performed before the interventions and on tenth day, first, third, and sixth months after the interventions.ResultsImprovement of epiphora was statistically significant at all visits when compared with values before injection (P<0.001) in both of groups. When two techniques were compared, difference in degree of epiphora before and after intervention was not statistically significant (P<0.05). In group 2, none of the patients had punctate epitheliopathy, although there was a significant decrease in Schirmer test results (P<0.001, paired t-test). In group 1, 9 cases (50%) had tube dislocation, 4 cases (22.2%) had obstruction, and granuloma formation. Five cases (25%) had ptosis in group 2.Conclusion Conjunctivodacryocystorhinostomy requires surgical experience, special postoperative care, and multiple revisions. As botulinum toxin-A injection in the lacrimal gland is technically easy, less-invasive, safe, with reversible effects, it can be considered as an alternative treatment in patients with proximal lacrimal system obstruction.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197871      PMCID: PMC4985683          DOI: 10.1038/eye.2016.88

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  27 in total

1.  Botulinum toxin A for the treatment of crocodile tears.

Authors:  Reha Yavuzer; Yavuz Başterzi; Fikret Akata
Journal:  Plast Reconstr Surg       Date:  2002-07       Impact factor: 4.730

2.  Jones' lacrimal canalicular bypass tubes: twenty-five years' experience.

Authors:  G E Rose; R A Welham
Journal:  Eye (Lond)       Date:  1991       Impact factor: 3.775

3.  Duration of botulinum toxin effect in the treatment of crocodile tears.

Authors:  Angel Nava-Castañeda; Jose L Tovilla-Canales; Victor Boullosa; Jose L Tovilla-y-Pomar; Maria H Monroy-Serrano; Victor Tapia-Guerra; Yonathan Garfias
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2006 Nov-Dec       Impact factor: 1.746

4.  Botulinum toxin for palliative treatment of epiphora in a patient with canalicular obstruction.

Authors:  Alexander H Tu; Eli L Chang
Journal:  Ophthalmology       Date:  2005-08       Impact factor: 12.079

5.  A modified glass tube for conjunctivodacryocystorhinostomy.

Authors:  G J Gladstone; A M Putterman
Journal:  Arch Ophthalmol       Date:  1985-08

6.  Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil.

Authors:  D J Haidak; B S Hurwitz; K Y Yeung
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

7.  Results of lacrimal gland botulinum toxin injection for epiphora in lacrimal obstruction and gustatory tearing.

Authors:  Ted H Wojno
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2011 Mar-Apr       Impact factor: 1.746

8.  Frosted jones pyrex tubes.

Authors:  Roger A Dailey; Robert N Tower
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2005-05       Impact factor: 1.746

9.  Conjunctivodacryocystorhinostomy with the frosted jones pyrex tube.

Authors:  Eric A Steele; Roger A Dailey
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2009 Jan-Feb       Impact factor: 1.746

View more
  8 in total

1.  Repeated injections of botulinum toxin-A for epiphora in lacrimal drainage disorders: qualitative and quantitative assessment.

Authors:  Chanjoo Ahn; Sunah Kang; Ho-Seok Sa
Journal:  Eye (Lond)       Date:  2019-02-14       Impact factor: 3.775

Review 2.  [Botulinum toxin in otorhinolaryngology - an update].

Authors:  R Laskawi; A Olthoff
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

Review 3.  A review on use of botulinum toxin for intractable lacrimal drainage disorders.

Authors:  Swati Singh; Mohammad Javed Ali; Friedrich Paulsen
Journal:  Int Ophthalmol       Date:  2017-08-01       Impact factor: 2.031

Review 4.  Lacrimal gland botulinum toxin injection for epiphora management.

Authors:  Johnathan Jeffers; Katherine Lucarelli; Sruti Akella; Pete Setabutr; Ted H Wojno; Vinay Aakalu
Journal:  Orbit       Date:  2021-08-15

5.  Long-term outcomes of lacrimal canalicular trephination with viscoelastic-assisted monocanalicular stenting for canalicular obstructions.

Authors:  Manpreet Singh; Manpreet Kaur; Zoramthara Zadeng; Manjula Sharma; Aditi Mehta; Pankaj Gupta
Journal:  Rom J Ophthalmol       Date:  2022 Jan-Mar

6.  Bilateral herpes simplex keratitis reactivation after lacrimal gland botulinum toxin injection.

Authors:  Purvasha Narang; Swati Singh; Vikas Mittal
Journal:  Indian J Ophthalmol       Date:  2018-05       Impact factor: 1.848

Review 7.  A Review of Periocular Botulinum Neurotoxin on the Tear Film Homeostasis and the Ocular Surface Change.

Authors:  Ren-Wen Ho; Po-Chiung Fang; Cheng-Hsien Chang; Yu-Peng Liu; Ming-Tse Kuo
Journal:  Toxins (Basel)       Date:  2019-01-24       Impact factor: 4.546

8.  Outcomes of lacrimal gland injection of botulinum toxin in functional versus nonfunctional epiphora.

Authors:  Swati Singh; Akshay Gopinathan Nair; Md Shahid Alam; Bipasha Mukherjee
Journal:  Oman J Ophthalmol       Date:  2019 May-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.